Capmatinib‑associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal‑epithelial transition exon 14: A case report
- Bing-Jie Lee
- Cheng-Yu Chang
Affiliations: Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000, Taiwan, R.O.C., Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000, Taiwan, R.O.C.
- Published online on: September 4, 2023 https://doi.org/10.3892/ol.2023.14042
Copyright: © Lee
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Capmatinib is a medication used to treat patients with non‑small cell lung cancer (NSCLC) who have a specific genetic mutation known as a mesenchymal‑epithelial transition exon 14 skipping mutation. Previous clinical trials have reported that capmatinib treatment has a high objective response rate in patients with this genetic mutation. However, there have also been rare reports of patients developing interstitial lung disease (ILD) following capmatinib treatment, which can be life‑threatening. The present case study reports the treatment of a patient who developed ILD after 6 weeks of capmatinib treatment for NSCLC, which was resolved following application of corticosteroids. The present case demonstrated that early recognition of the onset of ILD and discontinuation of capmatinib treatment, along with the prompt initiation of corticosteroid administration, can lead to complete resolution of ILD.